Joseph Kwong

Dr. Joseph Kwong

School of Medicine, Faculty of Medicine and Health Sciences, Keele University, Newcastle-under-Lyme ST5 5BG, UK
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Cancer Research
Verified
Journal Article
Open access
PDF file
HKHagen Kulbe
Hagen Kulbe
PCProbir Chakravarty
Probir Chakravarty
DLD. Andrew Leinster
D. Andrew Leinster
KCKellie A. Charles
Kellie A. Charles
Joseph KwongJoseph Kwong
Joseph Kwong
FBFrances R. Balkwill
Frances R. Balkwill
Constitutive production of inflammatory cytokines is a characteristic of many human malignant cell lines; however, the in vitro and in vivo interdependence of these cytokines, and their significance to the human cancer microenvironment, are both poorly understood. Here, we describe for the first time how three key cytokine/chemokine mediators of cancer-related inflammation, TNF, CXCL12, and interleukin 6, are involved in an autocrine cytokine network, the “TNF network,” in human ovarian cancer. We show that this network has paracrine actions on angiogenesis, infiltration of myeloid cells, and NOTCH signaling in both murine xenografts and human ovarian tumor biopsies. Neutralizing antibodies or siRNA to individual members of this TNF network reduced angiogenesis, myeloid cell infiltration, and experimental peritoneal ovarian tumor growth. The dependency of network genes on TNF was shown by their downregulation in tumor cells from patients with advanced ovarian cancer following the infusion of anti-TNF antibodies. Together, the findings define a network of inflammatory cytokine interactions that are crucial to tumor growth and validate this network as a key therapeutic target in ovarian cancer. Cancer Res; 72(1); 66–75. ©2011 AACR.

1 August 2020 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
TLTat San Lau
Tat San Lau
LCLoucia Kit Ying Chan
Loucia Kit Ying Chan
CMChi Wai Man
Chi Wai Man
CWChi Hang Wong
Chi Hang Wong
HLHo Sze Jacqueline Lee
Ho Sze Jacqueline Lee
Joseph KwongJoseph Kwong
Joseph Kwong
Emerging evidence shows that the efficacy of chemotherapeutic drugs is reliant on their capability to induce immunogenic cell death (ICD), thus transforming dying tumor cells into antitumor vaccines. We wanted to uncover potential therapeutic strategies that target ovarian cancer by having a better understanding of the standard-of-care chemotherapy treatment. Here, we showed in ovarian cancer that paclitaxel induced ICD-associated damage-associated molecular patterns (DAMP, such as CALR exposure, ATP secretion, and HMGB1 release) in vitro and elicited significant antitumor responses in tumor vaccination assays in vivo. Paclitaxel-induced TLR4 signaling was essential to the release of DAMPs, which led to the activation of NF-κB–mediated CCL2 transcription and IkappaB kinase 2–mediated SNARE-dependent vesicle exocytosis, thus exposing CALR on the cell surface. Paclitaxel induced endoplasmic reticulum stress, which triggered protein kinase R–like ER kinase activation and eukaryotic translation initiation factor 2α phosphorylation independent of TLR4. Paclitaxel chemotherapy induced T-cell infiltration in ovarian tumors of the responsive patients; CALR expression in primary ovarian tumors also correlated with patients' survival and patient response to chemotherapy. These findings suggest that the effectiveness of paclitaxel relied upon the activation of antitumor immunity through ICD via TLR4 and highlighted the importance of CALR expression in cancer cells as an indicator of response to paclitaxel chemotherapy in ovarian cancer.

11 March 2011 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TCT.K.H. Chung
T.K.H. Chung
TLT.S. Lau
T.S. Lau
TCT.H. Cheung
T.H. Cheung
SYS.F. Yim
S.F. Yim
KLKwok Wai Lo
Kwok Wai Lo
YWY.F. Wong
Y.F. Wong
MicroRNAs (miRNAs) regulate mRNA stability and protein expression, and certain miRNAs have been demonstrated to act either as oncogenes or tumor suppressors. Differential miRNA expression signatures have been documented in many human cancers but the role of miRNAs in endometrioid endometrial cancer (EEC) remains poorly understood. This study identifies significantly dysregulated miRNAs of EEC cells, and characterizes their impact on the malignant phenotype. We studied the expression of 365 human miRNAs using Taqman low density arrays in EECs and normal endometriums. Candidate differentially expressed miRNAs were validated by quantitative real‐time PCR. Expression of highly dysregulated miRNAs was examined in vitro through the effect of anti‐/pre‐miRNA transfection on the malignant phenotype. We identified 16 significantly dysregulated miRNAs in EEC and 7 of these are novel findings with respect to EEC. Antagonizing the function of miR‐7, miR‐194 and miR‐449b, or overexpressing miR‐204, repressed migration, invasion and extracellular matrix‐adhesion in HEC1A endometrial cancer cells. FOXC1 was determined as a target gene of miR‐204, and two binding sites in the 3′‐untranslated region were validated by dual luciferase reporter assay. FOXC1 expression was inversely related to miR‐204 expression in EEC. Functional analysis revealed the involvement of FOXC1 in migration and invasion of HEC1A cells. Our results present dysfunctional miRNAs in endometrial cancer and identify a crucial role for miR‐204‐FOXC1 interaction in endometrial cancer progression. This miRNA signature offers a potential biomarker for predicting EEC outcomes, and targeting of these cancer progression‐ and metastasis‐related miRNAs offers a novel potential therapeutic strategy for the disease.

1 January 2018 in Cancer Letters
Verified
Journal Article
Closed access
JWJianzhang Wang
Jianzhang Wang
CMChi Wai Man
Chi Wai Man
TCTak Hang Chan
Tak Hang Chan
Joseph KwongJoseph Kwong
Joseph Kwong
Chi Chiu WangChi Chiu Wang
Chi Chiu Wang

5 September 2012 in Angiogenesis
Verified
Journal Article
Closed access
PDF file
Chi Chiu WangChi Chiu Wang
Chi Chiu Wang
HXHui Xu
Hui Xu
CMChi Wai Man
Chi Wai Man
TZTao Zhang
Tao Zhang
KCKai On Chu
Kai On Chu
TCTak Hang Chan
Tak Hang Chan

9 February 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
TYTsz-Lun Yeung
Tsz-Lun Yeung
CLCecilia S. Leung
Cecilia S. Leung
KWKwong-Kwok Wong
Kwong-Kwok Wong
AGArthur Gutierrez-Hartmann
Arthur Gutierrez-Hartmann
Joseph KwongJoseph Kwong
Joseph Kwong
Samuel MokSamuel Mok
Samuel Mok
ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells